Shopping Cart

Your shopping cart is currently empty

GNE-3511 (Alias: GNE3511)

Name: GNE-3511
Brand: TargetMol
SKU: T3707
Price: 43 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T3707 Copy Product Info

Purity: 99.51%

😃Good

GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.

GNE-3511

Copy Product Info

😃Good

Catalog No. T3707

Alias GNE3511

GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.

Cas No. 1496581-76-0

Customer service consultation

Pack Size	Price	USA Stock	Global Stock
10 mg	$43	In Stock	In Stock
25 mg	$73	In Stock	In Stock
50 mg	$118	In Stock	In Stock
100 mg	$197	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$47	In Stock	In Stock

In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.51%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

GNE-3511 AI Summary

GNE-3511 exhibits a wide range of bioactivities, including notable inhibition of multiple kinases such as DLK, JNK, MLK, EphA1, LCK, Src, STK16, Syk, Flt3, Src_N1, and MKK, suggesting its significant role in signaling pathways modulation. It is involved in drug transport mechanisms demonstrated by efflux activity in MDCK cells expressing human MDR1. The compound shows promising neuroprotective activity in rat embryo DRG neurons, indicating potential therapeutic effects for nerve cell protection. Additionally, it has moderate oral bioavailability and variable pharmacokinetic profiles across different animal models. For antiviral applications, GNE-3511 exhibits 6.75% inhibition against the SARS-CoV-2 3CL-Pro protease at a concentration of 20µM and shows activity in reducing SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10µM, with a 2.57% inhibition percentage observed after 48 hours of exposure. The compound also demonstrates cell-type-specific cytotoxicity, impacting cell viability differently across various cell lines. In U2OS cells, it mostly promotes growth, ranging from 0.18 to 0.88, while having mixed effects on human fibroblast and HEK293T cells, with growth rates ranging from -1.0 to 0.43 and -0.9 to 0.85, respectively. It also exhibits significant cytotoxicity against human HepG2 cells, with an IC50 value of 1900.0 nM in the CellTiter-Glo luminescent cell viability assay. Finally, GNE-3511 demonstrates potent inhibition with an IC50 value of 3.0 nM in both DLK and LZK assays..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	GNE-3511 is a potent and selective dual leucine zipper kinase inhibitors.
Targets&IC50	DLK:0.5 nM. (Ki)
Synonyms	GNE3511

Chemical Properties

Molecular Weight	440.49
Formula	C₂₃H₂₆F₂N₆O
Cas No.	1496581-76-0
Smiles	FC1(F)CCN(C1)c1cc(cc(Nc2cc(ccn2)C#N)n1)C1CCN(CC1)C1COC1
Relative Density.	1.37 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 6.25 mg/mL (14.19 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (2.27 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2702 mL	11.3510 mL	22.7020 mL	113.5100 mL
5 mM	0.4540 mL	2.2702 mL	4.5404 mL	22.7020 mL
10 mM	0.2270 mL	1.1351 mL	2.2702 mL	11.3510 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc